Abbott Laboratories (XSWX:ABT) Ending Cash Position: CHF5,356 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:ABT Abbott Laboratories XSWX:ABT
70 GF Score
Price CHF73.00
GF Value CHF106.67
! 1 Warning Sign
View Full Analysis

What is Abbott Laboratories Ending Cash Position?

Abbott Laboratories XSWX:ABT -5.81% 70 Ending Cash Position is CHF5,356 Mil as of Mar. 2026. GuruFocus rates XSWX:ABT with a GF Score™ of 70/100 and a GF Value™ of CHF106.67. The stock has 1 warning sign investors should review.

Abbott Laboratories's Ending Cash Position for the quarter that ended in Mar. 2026 was CHF5,356 Mil.

Abbott Laboratories's quarterly Ending Cash Position increased from Sep. 2025 (CHF5,980 Mil) to Dec. 2025 (CHF6,791 Mil) but then declined from Dec. 2025 (CHF6,791 Mil) to Mar. 2026 (CHF5,356 Mil).

Abbott Laboratories's annual Ending Cash Position increased from Dec. 2023 (CHF5,964 Mil) to Dec. 2024 (CHF6,790 Mil) and increased from Dec. 2024 (CHF6,790 Mil) to Dec. 2025 (CHF6,791 Mil).

Abbott Laboratories Ending Cash Position Related Terms

Abbott Laboratories Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Abbott Laboratories's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abbott Laboratories Ending Cash Position Chart

Abbott Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9,024.88 9,206.07 5,963.66 6,790.43 6,791.18

Abbott Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,771.68 5,652.55 5,979.51 6,791.18 5,356.00
XSWX:ABT
70GF Score
Abbott Laboratories XSWX:ABT
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abbott Laboratories Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Abbott Laboratories's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=6069.191+721.991
=6,791

Abbott Laboratories's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=6709.37+-1353.368
=5,356

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of CHF5,356 Mil mean?
Abbott Laboratories (XSWX:ABT) has a Ending Cash Position of CHF5,356 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Abbott Laboratories and its competitors.
Is Abbott Laboratories' Ending Cash Position too high?
Abbott Laboratories' current Ending Cash Position is CHF5,356 Mil. Overall, Abbott Laboratories has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories' Ending Cash Position compare to SYK and MDT?
Abbott Laboratories' Ending Cash Position of CHF5,356 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Abbott Laboratories and its competitors. Abbott Laboratories's current Ending Cash Position is CHF5,356 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories stock overvalued right now?
Abbott Laboratories (XSWX:ABT) has a current Ending Cash Position of CHF5,356 Mil. The stock's GF Value™ is CHF106.67, compared to a current price of CHF73.00 — trading 31.6% below its estimated fair value. The current Ending Cash Position is CHF5,356 Mil. Abbott Laboratories' overall GF Score™ is 70/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Abbott Laboratories (XSWX:ABT), the current Ending Cash Position is CHF5,356 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abbott Laboratories (XSWX:ABT) Overvalued in 2026?

Based on GuruFocus' analysis, Abbott Laboratories stock appears to be undervalued. The current stock price of CHF73.00 is trading 31.6% below its estimated GF Value™ of CHF106.67.

Key valuation signals for XSWX:ABT:

  • Ending Cash Position: CHF5,356 Mil
  • GF Value™: CHF106.67 vs. price of CHF73.00 (31.6% below fair value)
  • GF Score™: 70/100 with 1 warning sign

No single metric tells the full story. See the XSWX:ABT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abbott Laboratories Business Description

Address 100 Abbott Park Road, Abbott Park, IL, USA, 60064-6400
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
70GF Score

Get the complete analysis for XSWX:ABT

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF73.00
Price
CHF106.67
GF Value